Navigation Links
BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog
Date:12/8/2009

PLYMOUTH MEETING, Pa., Dec. 8 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company") today announced that seventy eight of the Company's drugs have been included in China's National (Medical) Insurance Catalog (the "2009 NIC"), which was released by China's Ministry of Human Resources and Social Security on November 30, 2009 as part of China's health care reform plan. According to the Chinese government, ninety percent of China's citizens will be covered by a universal healthcare system by the end of calendar 2010.

The 2009 NIC is China's health care reform plan's official drug reimbursement list and includes 2,151 drugs in total. Seventy eight of BMP Sunstone's products have been included in the 2009 NIC, twelve of which are new additions from the last published catalog in 2004. These new additions include some of BMP Sunstone's best selling products such as Confort, a women's health treatment for vaginal infections, and Propess, a first line treatment for labor induction in late-stage pregnancy. The Company's Amoxicillin and Amoxicillin & Clavulanate Potassium products, which treat cough and cold symptoms, were also added to the 2009 NIC. In addition, the Company's thalassemia medication, Ferriprox, has been preliminarily added to Guangdong Province's Medical Insurance Catalog.

Mr. David Gao, Chief Executive Officer of BMP Sunstone, commented, "We are delighted to have twelve new drugs and a total of seventy eight of our products included in China's National Insurance Catalog. The NIC is a vital part of the universal healthcare system, and will greatly expand the addressable pharmaceutical market in China. We are especially pleased about the inclusion of two of our best-performing products, Confort and Propess, as well as our cough and cold products, in the NIC and the preliminary inclusion of Ferriprox in Guangdong Province's Medical Insurance Catalog. Guangdong Province has the highest incidence of thalassemia in China and treatment for this disorder can be very expensive. Therefore, we believe that the potential for partial reimbursement in Guangdong Province will boost sales of Ferriprox throughout that province. We believe that the inclusion of our products in the insurance catalogs will strengthen our brand recognition and accelerate our penetration into our key therapeutic areas, including women's and children's health."

About BMP Sunstone Corporation

BMP Sunstone Corporation ("BMP Sunstone" or the "Company") is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Through Sunstone Pharmaceutical Co. Ltd., the Company manufactures leading pediatric and women's health products, including two of China's most recognized brands, "Hao Wawa" and "Confort," sold throughout the country in approximately 120,000 pharmacies. The Company also markets a portfolio of products under exclusive multi-year licenses into China, primarily focused on women's health and pediatrics, as well as provides pharmaceutical distribution services through subsidiaries in Beijing and Shanghai. BMP Sunstone's main office is in Beijing, with a U.S. office in Plymouth Meeting, PA. For more information, please visit http://www.bmpsunstone.com .

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including but not limited to statements about the Company's strategic and market penetration strategies and the potential effects of the listing of the Company's products on China's National (Medical) Insurance Catalog. These statements are subject to uncertainties and risks including, but not limited to, operating performance, general financial, economic, and political conditions affecting the biotechnology and pharmaceutical industries and the Chinese pharmaceutical market, the ability to timely manufacture and distribute the Company's products and other risks contained in reports filed by the Company with the Securities and Exchange Commission. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

    For more information, please contact:

    Integrated Corporate Relations, Inc.
    (Investor Relations)

     Ashley M. Ammon
     Tel:   +1-646-277-1227

     Christine Duan
     Tel:   +1-203-682-8200

SOURCE BMP Sunstone Corporation


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... WESTWOOD, Mass. , Oct. 4, 2017  According to the Centers ... by the end of October . PhysicianOne Urgent Care is helping communities ... Westchester, NY , by offering no-cost* flu shots through ... , as mandated by certain health insurance regulations. ... The best time to get a flu shot is by ...
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
(Date:10/2/2017)... ORLANDO, Fla. , Oct. 2, 2017  AllianceRx ... services company formed by Walgreens and pharmacy benefit manager ... of its new brand, which included the unveiling of ... Fla. , as well as at a few ... introduces the new brand to patients, some of whom ...
Breaking Medicine Technology:
(Date:10/13/2017)... WI (PRWEB) , ... October 13, 2017 , ... As ... in medicine known as “patient engagement.” The patient is doing more than filling out ... partners. , “There is an increasing emphasis in health care and research on ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
Breaking Medicine News(10 mins):